1. Home
  2. NTLA vs DCO Comparison

NTLA vs DCO Comparison

Compare NTLA & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • DCO
  • Stock Information
  • Founded
  • NTLA 2014
  • DCO 1849
  • Country
  • NTLA United States
  • DCO United States
  • Employees
  • NTLA N/A
  • DCO N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • DCO Military/Government/Technical
  • Sector
  • NTLA Health Care
  • DCO Industrials
  • Exchange
  • NTLA Nasdaq
  • DCO Nasdaq
  • Market Cap
  • NTLA 1.2B
  • DCO 1.4B
  • IPO Year
  • NTLA 2016
  • DCO N/A
  • Fundamental
  • Price
  • NTLA $10.90
  • DCO $91.45
  • Analyst Decision
  • NTLA Buy
  • DCO Strong Buy
  • Analyst Count
  • NTLA 20
  • DCO 4
  • Target Price
  • NTLA $32.30
  • DCO $119.75
  • AVG Volume (30 Days)
  • NTLA 5.0M
  • DCO 131.8K
  • Earning Date
  • NTLA 08-07-2025
  • DCO 08-07-2025
  • Dividend Yield
  • NTLA N/A
  • DCO N/A
  • EPS Growth
  • NTLA N/A
  • DCO 73.00
  • EPS
  • NTLA N/A
  • DCO 2.65
  • Revenue
  • NTLA $52,857,000.00
  • DCO $795,078,000.00
  • Revenue This Year
  • NTLA N/A
  • DCO $6.05
  • Revenue Next Year
  • NTLA N/A
  • DCO $6.91
  • P/E Ratio
  • NTLA N/A
  • DCO $34.84
  • Revenue Growth
  • NTLA 14.99
  • DCO 2.42
  • 52 Week Low
  • NTLA $5.90
  • DCO $51.76
  • 52 Week High
  • NTLA $24.16
  • DCO $94.00
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 45.06
  • DCO 58.37
  • Support Level
  • NTLA $10.57
  • DCO $87.80
  • Resistance Level
  • NTLA $11.51
  • DCO $94.00
  • Average True Range (ATR)
  • NTLA 0.69
  • DCO 3.07
  • MACD
  • NTLA -0.26
  • DCO -0.37
  • Stochastic Oscillator
  • NTLA 10.44
  • DCO 65.54

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: